This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Viatris (VTRS) Up 13.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Viatris (VTRS) Q1 Earnings Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.
Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 4.17% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.21, moving -1.16% from the previous trading session.
Earnings Preview: Viatris (VTRS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.39, moving +1.07% from the previous trading session.
Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.92, moving +1.96% from the previous trading session.
Viatris (VTRS) Stock Moves -0.28%: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.67, moving -0.28% from the previous trading session.
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.67, moving -1.66% from the previous trading session.
Theravance's (TBPH) Hypotension Study Misses Primary Goal
by Zacks Equity Research
Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.99, moving -1.7% from the previous trading session.
Viatris (VTRS) Up 10.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris (VTRS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $10.88, marking a +0.28% move from the previous day.
Viatris (VTRS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $10.77, marking a +1.03% move from the previous day.
Viatris (VTRS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $9.96, moving +1.53% from the previous trading session.
Why is Viatris (VTRS) Stock Down 25% in the Year So Far?
by Zacks Equity Research
Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.
Company News for Mar 1, 2022
by Zacks Equity Research
Companies In The News Are: JLL, TGNA, XRAY, VTRS.
Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked
by Zacks Equity Research
Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.
Viatris (VTRS) Q4 Earnings Miss Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of -2.44% and 0.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Viatris (VTRS) Might Surprise This Earnings Season
by Zacks Equity Research
Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.
Viatris (VTRS) Stock Moves -1.58%: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $14.32, moving -1.58% from the previous trading session.